Why the study?
The incremental value of PET MPI over CCTA in predicting short- and long-term outcomes using machine learning approaches was unknown.
Does adding PET MPI data to CCTA improve the prediction of adverse events in patients with suspected CAD?
Cohort (n=2,284)
Does adding PET MPI data to CCTA improve the prediction of adverse events in patients with suspected CAD?
Adding downstream PET MPI to CCTA provides incremental prognostic value for predicting adverse events up to 4 years in patients with suspected CAD.
May support incremental risk stratification with PET MPI added to CCTA in suspected CAD; leaves open need for randomized outcome trials.
AIMS: To evaluate the incremental value of positron emission tomography (PET) myocardial perfusion imaging (MPI) over coronary computed tomography angiography (CCTA) in predicting short- and long-term outcome using machine learning (ML) approaches. METHODS AND RESULTS: A total of 2411 patients with clinically suspected coronary artery disease (CAD) underwent CCTA, out of whom 891 patients were admitted to downstream PET MPI for haemodynamic evaluation of obstructive coronary stenosis. Two sets of Extreme Gradient Boosting (XGBoost) ML models were trained, one with all the clinical and imaging variables (including PET) and the other with only clinical and CCTA-based variables. Difference in the performance of the two sets was analysed by means of area under the receiver operating characteristic curve (AUC). After the removal of incomplete data entries, 2284 patients remained for further analysis. During the 8-year follow-up, 210 adverse events occurred including 59 myocardial infarctions, 35 unstable angina pectoris, and 116 deaths. The PET MPI data improved the outcome prediction over CCTA during the first 4 years of the observation time and the highest AUC was at the observation time of Year 1 (0.82, 95% confidence interval 0.804-0.827). After that, there was no significant incremental prognostic value by PET MPI. CONCLUSION: PET MPI variables improve the prediction of adverse events beyond CCTA imaging alone for the first 4 years of follow-up. This illustrates the complementary nature of anatomic and functional information in predicting the outcome of patients with suspected CAD.
No takes yet. Share an insight, caveat, or question.
Lehtonen et al. (2023) conducted a cohort in Clinically suspected coronary artery disease (CAD) (n=2,284). PET MPI added to CCTA vs. CCTA alone was evaluated on Adverse events (myocardial infarction, unstable angina pectoris, and death) (AUC 0.82, 95% CI 0.804-0.827).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: